Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could ease rare muscle disease symptoms

NCT ID NCT07564271

Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 5 times

Summary

This study is testing a drug called deucravacitinib in 10 adults with idiopathic inflammatory myopathies, a group of rare diseases that cause muscle inflammation and weakness. Participants will take one pill daily for 6 months. Researchers will track symptom changes and lab results to see if the drug is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deucravacitinib (a pill taken once a day)
What this could lead to
If it works, this could point toward a new treatment option for people with inflammatory muscle diseases who haven't responded to standard therapies.
What could go wrong
This is a very small, early observational study with only 10 participants, so results may not apply to everyone. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Started

Oct 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Clinical Rheumatologist

Ages

18 to 75 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults between 18 years and 75 years of age. * Adults with active idiopathic inflammatory myopathies will be enrolled, meeting the Bohan \& Peter DM/PM or American College of Rheumatology(ACR) \& European allance of associations for rheumatology(EULAR)(2017) diagnostic criteria. * Active disease: MDAAT skin VAS ≥ 3 cm, with at least 3 core indicators abnormal; * Inadequate response to or intolerance of conventional treatments (such as glucocorticoids, immunosuppressants). Exclusion Criteria: * Any subject meeting either of the following criteria should be excluded: * Combined with other systemic autoimmune diseases; * Severe hepatic and renal dysfunction; * Active infections (such as tuberculosis, hepatitis B, HIV); * Pregnant or lactating women; * Previous use of JAK inhibitors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic inflammatory myopathies (IIMS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic inflammatory myopathies (IIMS)

Contacts and locations

Locations

  • Department of Rheumatology and Immunology, Peking University People's Hospital

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.